Impax Submits Additional Information to FDA

Impax Laboratories, Inc. announced that it has submitted information to the U.S. Food and Drug Administration (FDA) in response to the notice of rescission related to Impax’s abbreviated new drug application (ANDA) for oxymorphone hydrochloride extended-release tablets CII, a generic version of Opana ER.
Business Wire